Why rigid application of the window of opportunity may harm older women?
Open Access
- 7 October 2026
- journal article
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 42 (1)
Abstract
No abstract availableFunding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (304048/2026-7)
This publication has 12 references indexed in Scilit:
- Neurokinin pathway antagonists for vasomotor symptoms in women with breast cancer: focus on elinzanetant and fezolinetantThe Breast, 2026
- Survival After the First Myocardial Infarction in Older Women: A Prospective Cohort Analysis From the WHIJournal of the American Heart Association, 2026
- Menopausal hormone therapy reduces the risk of fracture regardless of falls risk or baseline FRAX probability—results from the Women’s Health Initiative hormone therapy trialsOsteoporosis International, 2022
- The British Menopause Society & Women’s Health Concern 2020 recommendations on hormone replacement therapy in menopausal womenPost Reproductive Health, 2020
- Moderate to severe vasomotor and sexual symptoms remain problematic for women aged 60 to 65 yearsMenopause, 2015
- Risk of Osteoporotic Fractures After Discontinuation of Menopausal Hormone Therapy: Results From the E3N CohortAmerican Journal of Epidemiology, 2011
- A “window of opportunity:” The reduction of coronary heart disease and total mortality with menopausal therapies is age- and time-dependentBrain Research, 2011
- Postmenopausal hormone therapy and regional brain volumesNeurology, 2009
- Fracture Incidence in Relation to the Pattern of Use of Hormone Therapy in Postmenopausal WomenJAMA, 2004
- Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal WomenJAMA, 2003